• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Survival May Not Differ by Race in Multiple Myeloma Treated With Abecma

by | Nov 6, 2023 | Uncategorized

Source: CureToday articles Researchers have found that, among patients with relapsed/refractory multiple myeloma who received treatment with the CAR-T cell therapy Abecma, race and ethnicity played roles in safety and response but not survival. Read...

CAR-T outcomes for multiple myeloma similar regardless of race, ethnicity

by | Oct 30, 2023 | Uncategorized

Black, Hispanic and white individuals treated with idecabtagene vicleucel for relapsed or refractory multiple myeloma experienced similar PFS and OS, according to study results published in Blood Advances.The findings should be confirmed in larger samples of diverse...

My Journey Through Multiple Myeloma: A Rebirth

by | Oct 25, 2023 | Uncategorized

Source: CureToday articles Braving the storm that is cancer. Read More

To Improve Multiple Myeloma Survival, Diabetes Management Cannot Be Ignored

by | Oct 17, 2023 | Uncategorized

Source: CureToday articles Patients with cancer and diabetes need to carefully co-manage both diseases, as one expert tells CURE. Read More

New Trial Doses STAR-LLD in Patients With Multiple Myeloma

by | Oct 14, 2023 | Uncategorized

Source: CureToday articles A new phase 1 trial is testing their first patients with STAR-LLD in the treatment of patients with multiple myeloma. Read More

Diabetes lowers survival among white, but not Black patients with multiple myeloma

by | Oct 9, 2023 | Uncategorized

Patients with both multiple myeloma and diabetes experienced reduced OS compared with those without diabetes, according to study results published in Blood Advances.Of note, results of a subgroup analysis specifically showed worse OS among white patients with multiple...
« Older Entries
Next Entries »

Recent Content

  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
  • Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
  • The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
  • FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma
  • Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
  • Unexpected Support in Tough Times With Multiple Myeloma
  • The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
  • Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
  • Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT